Liraglutide is a glucagon-like peptide-1 receptor agonist that approved prescribing information documents as a once-daily subcutaneous injection, with the target dose set by the indication rather than by body weight. The published labeling describes a slow weekly titration from a sub-therapeutic 0.6 mg starting dose, a schedule built to let the gastrointestinal system adapt before the maintenance dose is reached. Because the drug carries a half-life near 13 hours, the record reports steady once-daily exposure independent of meal timing.
Approved labeling documents liraglutide as a once-daily subcutaneous injection titrated weekly from 0.6 mg to an indication-specific maintenance dose of 1.8 mg for type 2 diabetes or 3.0 mg for chronic weight management.
The two approved indications share one molecule but part ways at the maintenance dose, a distinction the labeling makes concrete by marketing them as separate pen products with different maximum dial settings. In type 2 diabetes the documented ceiling is 1.8 mg once daily, the point at which trials found glycemic benefit flattening as gastrointestinal complaints kept rising; in chronic weight management the record supports a higher 3.0 mg maintenance dose because the appetite and satiety effects continue climbing across that range.
| Criterion | Type 2 diabetes | Chronic weight management |
|---|---|---|
| Starting dose | 0.6 mg once daily, week one | 0.6 mg once daily, week one |
| Titration steps | 0.6 to 1.2 to 1.8 mg | 0.6 to 1.2 to 1.8 to 2.4 to 3.0 mg |
| Maintenance ceiling | 1.8 mg once daily | 3.0 mg once daily |
| Reason for the cap | Glycemic benefit plateaus | Appetite effect keeps rising |
The approved diabetes regimen tops out at 1.8 mg once daily while the chronic weight-management regimen continues to a 3.0 mg maintenance dose, and the two are sold as separate pen products so a diabetes pen cannot be dialed past its intended range.
Titration is the deliberate, gradual escalation the labeling prescribes so the gut can adapt to receptor activation before the therapeutic dose arrives. The conventional schedule holds each step for at least a week, and the 0.6 mg opening dose sits intentionally below the level that produces meaningful clinical effect, existing only to introduce the drug slowly. Published tolerability data identify pushing this escalation too fast as the single most common avoidable reason a patient abandons therapy.
The standard titration holds each dose for at least one week, opening at a sub-therapeutic 0.6 mg and advancing through 1.2 and 1.8 mg, because published tolerability data tie too-fast escalation to the nausea, vomiting, and diarrhea that most often end treatment.
Published administration guidance describes liraglutide as a subcutaneous injection placed in fat, never into muscle or vein, using the abdomen, the front of the thigh, or the back of the upper arm. Rotating the site with each dose is documented as the way lipohypertrophy is avoided, the lumpy fat thickening that develops with repeated use of one spot and that can distort absorption.
Administration guidance places liraglutide in the subcutaneous fat of the abdomen, thigh, or upper arm using a 4-to-8 mm needle held about six seconds after injection, with the site rotated each dose to prevent lipohypertrophy.
Timing is one of liraglutide's more forgiving features in the published record. The labeling documents administration at any hour, with or without food, because a half-life near 13 hours holds steady plasma levels across the full 24-hour interval rather than tracking a single meal. That sets it apart from short-acting GLP-1 receptor agonists, which the literature ties to a fixed pre-meal window.
Liraglutide's roughly 13-hour half-life is documented as supporting administration at any time of day, with or without food, unlike short-acting GLP-1 receptor agonists that the literature restricts to a set pre-meal window.
The published guidance for a missed dose turns on how much time has passed since the last injection. A single skipped daily dose is documented as inconsequential to steady-state effect, while a gap beyond three days is treated very differently, because the body's tolerance to the drug fades over that span.
Published guidance documents a single missed liraglutide dose as skipped rather than doubled, but a gap of more than three days as grounds to reinitiate at the 0.6 mg starting dose and re-titrate, because tolerance to the drug fades over that interval.
Storage rules split cleanly at the moment a pen is first used, and the published product information draws a firm line between the two states. The peptide's stability depends on it: freezing is prohibited outright, and a solution that has frozen is documented as denatured and unusable even if it looks normal after thawing.
| Condition | Unopened pen | In-use pen |
|---|---|---|
| Temperature | 2 to 8 C, refrigerated | Up to ~30 C or refrigerated |
| Time limit | Full labeled shelf life | About 30 days from first use |
| Freezing | Prohibited; discard if frozen | Prohibited; discard if frozen |
| Light and heat | Capped, shielded from light | Capped, shielded from light and heat |
Product information documents unopened pens as refrigerated at 2 to 8 C and an in-use pen as usable for about 30 days at up to 30 C or refrigerated, with freezing prohibited because a frozen peptide solution is denatured and must be discarded.
Liraglutide is not cleared mainly by the kidneys or liver, so the labeling mandates no fixed dose reduction tied to a specific level of organ impairment. What the record documents instead is a posture that grows more cautious as impairment advances, with the larger renal risk being indirect: gastrointestinal side effects can drive the dehydration that precipitates acute kidney injury.
Because liraglutide is not cleared primarily by the kidneys or liver, the labeling sets no fixed dose reduction for organ impairment or age, though the record documents heightened caution and closer monitoring as renal impairment advances, driven mainly by dehydration-related acute kidney injury risk.
The approved ceilings differ by indication, 1.8 mg once daily for type 2 diabetes and 3.0 mg once daily for chronic weight management, and each cap marks where the published risk-benefit balance turns unfavorable. Doses above the studied range are not sanctioned, because the record shows no proportional benefit past the ceiling and a rising burden of adverse effects.
The approved maximum is 1.8 mg once daily for type 2 diabetes and 3.0 mg once daily for chronic weight management, ceilings set where added dose stops delivering proportional benefit and adverse effects rise, with no specific antidote documented for overdose.
The prefilled pen is documented as a self-contained metering device that holds a fixed volume and dispenses discrete doses, with internal stops that keep the dial from exceeding the indication's approved amount. That built-in limit is why a single pen can carry many days of small doses yet fewer at the maximum setting.
The prefilled pen meters each dose through a rotating dial limited by internal stops to the indication's approved maximum, and a flow check before first use clears air while the dose counter returning to zero confirms the full metered amount was delivered.
Educational use only. This article describes what the published scientific and clinical literature reports about Liraglutide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
